The PE Ratio as of December 2024 (TTM) for Innovent Biologics, Inc. (IVBXF) is -41.64

According to Innovent Biologics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -41.64. This represents a change of -20.23% compared to the average of -52.20 of the last 4 quarters.

Innovent Biologics, Inc. (IVBXF) Historical PE Ratio (quarterly & annually)

How has IVBXF PE Ratio performed in the past?

The mean historical PE Ratio of Innovent Biologics, Inc. over the last ten years is -33.58. The current -41.64 PE Ratio has changed 12.30% with respect to the historical average. Over the past ten years (40 quarters), IVBXF's PE Ratio was at its highest in in the June 2018 quarter at 5.96. The PE Ratio was at its lowest in in the March 2023 quarter at -169.58.

Innovent Biologics, Inc. (IVBXF) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Innovent Biologics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Innovent Biologics, Inc. (IVBXF) Average PE Ratio

How has IVBXF PE Ratio performed in the past?

The current PE Ratio of Innovent Biologics, Inc. (IVBXF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Innovent Biologics, Inc. (IVBXF) PE Ratio vs. Peers

How is IVBXF’s PE Ratio compared to its peers?

Innovent Biologics, Inc.’s PE Ratio is less than Telix Pharmaceuticals Limited (267.93), less than Keros Therapeutics, Inc. (-3.32), less than MAIA Biotechnology, Inc. (-1.83), less than Graphite Bio, Inc. (-0.13), less than Genscript Biotech Corporation (0), less than Oxford Nanopore Technologies plc (-15.38), less than Nuvalent, Inc. (-5.79), less than Crinetics Pharmaceuticals, Inc. (-24.20), less than Inhibrx Biosciences, Inc. (-15.54), less than Merus N.V. (0.14), less than Lyell Immunopharma, Inc. (-11.84), less than Kronos Bio, Inc. (-0.77), less than Theseus Pharmaceuticals, Inc. (-0.67), less than Cullinan Oncology, Inc. (-6.29), less than Mersana Therapeutics, Inc. (-4.99), less than Relay Therapeutics, Inc. (-2.66), less than Arcus Biosciences, Inc. (-1.72), less than null (-5.39),

Build a custom stock screener for Innovent Biologics, Inc. (IVBXF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innovent Biologics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Innovent Biologics, Inc. (IVBXF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Innovent Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.